Aytu BioPharma Announces Submission of Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval SupplementAccesswire • 07/10/23
Aytu BioPharma Announces Closing of $4.0 Million Public Offering Priced At-the-MarketAccesswire • 06/13/23
Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New DirectorAccesswire • 06/09/23
Aytu BioPharma to Report Third Quarter Fiscal 2023 Financial Results on May 11, 2023Accesswire • 05/04/23
Aytu BioPharma Announces Approval of Adzenys XR-ODT(R)Manufacturing Site TransferAccesswire • 04/27/23
Aytu BioPharma Inc. (AYTU) May Find a Bottom Soon, Here's Why You Should Buy the Stock NowZacks Investment Research • 03/06/23
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 21, 2023Accesswire • 02/21/23
Aytu BioPharma Announces Delayed Filing of Second Quarter Fiscal 2023 Financial ResultsAccesswire • 02/14/23
Aytu BioPharma to Report Second Quarter Fiscal 2023 Financial Results on February 14, 2023Accesswire • 02/07/23
Aytu BioPharma to Present at Lytham Partners Investor Select Conference on January 31Accesswire • 01/24/23
Aytu BioPharma, Inc Continues Availability of Adzenys XR-ODT(R) as the Only FDA-Approved Orally Disintegrating Tablet (ODT) Medication that is Bioequivalent to Adderall XR(R) for ADHD PatientsAccesswire • 01/10/23
Bears are Losing Control Over Aytu BioPharma Inc. (AYTU), Here's Why It's a 'Buy' NowZacks Investment Research • 11/30/22
Aytu BioPharma Announces Highest Weekly Adzenys XR-ODT(R) Prescriptions Generated Since Inception of RxConnectAccesswire • 11/30/22
Aytu BioPharma Receives a 180-Day Extension by Nasdaq to Regain Compliance with Bid Price RuleAccesswire • 11/22/22
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Second Year in a RowAccesswire • 11/17/22